Different effects of the ABCG2 c.421C>A SNP on the pharmacokinetics of fluvastatin, pravastatin and simvastatin.
about
Genetic factors affecting statin concentrations and subsequent myopathy: a HuGENet systematic reviewPediatric Statin Administration: Navigating a Frontier with Limited DataEvaluation of drug interactions of GSK1292263 (a GPR119 agonist) with statins: from in vitro data to clinical study design.Pharmacogenetic determinants associated with sunitinib-induced toxicity and ethnic difference in Korean metastatic renal cell carcinoma patients.Decreased exposure of simvastatin and simvastatin acid in a rat model of type 2 diabetes.Pharmacogenetics of Statin-Induced Myopathy: A Focused Review of the Clinical Translation of Pharmacokinetic Genetic VariantsStructure and function of the human breast cancer resistance protein (BCRP/ABCG2).Pharmacogenetic Foundations of Therapeutic Efficacy and Adverse Events of Statins.Role of the breast cancer resistance protein (BCRP/ABCG2) in drug transport--an update.Eltrombopag increases plasma rosuvastatin exposure in healthy volunteers.Creatine kinase elevation caused by a combination of fluvastatin and telmisartan in a patient heterozygous for the CYP2C9*3 and ABCC2 -24C > T variants: a case report.Pharmacogenomics of membrane transporters: past, present and futureIndividualized risk for statin-induced myopathy: current knowledge, emerging challenges and potential solutionsEffects of Fostamatinib on the Pharmacokinetics of Oral Contraceptive, Warfarin, and the Statins Rosuvastatin and Simvastatin: Results From Phase I Clinical Studies.The rs1142345 in TPMT Affects the Therapeutic Effect of Traditional Hypoglycemic Herbs in Prediabetes.Drug-drug interaction studies: regulatory guidance and an industry perspectiveMolecular mechanisms of statin intoleranceTransporter pharmacogenetics and statin toxicity.Drug transport by breast cancer resistance protein.The ABCG2 transporter and its relations with the pharmacokinetics, drug interaction and lipid-lowering effects of statins.Impact of SLCO1B1 (OATP1B1) and ABCG2 (BCRP) genetic polymorphisms and inhibition on LDL-C lowering and myopathy of statins.Pharmacogenomics and adverse drug reactions: the case of statins.Towards safer and more predictable drug treatment--reflections from studies of the First BCPT Prize awardee.Impact of drug transporter pharmacogenomics on pharmacokinetic and pharmacodynamic variability - considerations for drug development.Pediatric pharmacogenomics: a systematic assessment of ontogeny and genetic variation to guide the design of statin studies in children.Understanding the critical disposition pathways of statins to assess drug-drug interaction risk during drug development: it's not just about OATP1B1.Effect of the ATP-binding cassette transporter ABCG2 on pharmacokinetics: experimental findings and clinical implications.Drug-drug interactions between HMG-CoA reductase inhibitors (statins) and antiviral protease inhibitors.Pharmacogenomics of lipid-lowering therapies.Lipid-lowing pharmacogenomics in Chinese patients.Evaluation of the pharmacokinetics and drug interactions of the two recently developed statins, rosuvastatin and pitavastatin.Polymorphisms of the drug transporters ABCB1, ABCG2, ABCC2 and ABCC3 and their impact on drug bioavailability and clinical relevance.Intestinal and hepatic drug transporters: pharmacokinetic, pathophysiological, and pharmacogenetic roles.Impact of Pharmacogenetics on Efficacy and Safety of Statin Therapy for Dyslipidemia.Deferasirox pharmacogenetic influence on pharmacokinetic, efficacy and toxicity in a cohort of pediatric patients.Importance of Hepatic Transporters in Clinical Disposition of Drugs and Their Metabolites.Impact of Transporter Polymorphisms on Drug Development: Is It Clinically Significant?Renal Drug Transporters and Drug Interactions.Subtle Structural Differences Trigger Inhibitory Activity of Propafenone Analogues at the Two Polyspecific ABC Transporters: P-Glycoprotein (P-gp) and Breast Cancer Resistance Protein (BCRP).What is a relevant statin concentration in cell experiments claiming pleiotropic effects?
P2860
Q26823434-DF935668-94EF-4B15-934F-05277EA4C008Q28068014-4A6BCBA3-071A-4892-8A45-458203D438D7Q30582571-A82F15E7-D1CD-4B9C-9279-9E216E55430CQ33410206-C20CC4AA-5C86-44C8-B43B-1D301819837AQ34138321-27D4630C-D791-49C0-B05B-1CD6E02A4454Q34163351-D17A46B0-900F-48CD-8ACA-DAEDC00521AAQ34176588-E64D0CAC-5479-4DEA-BC5C-0F949945C9FCQ34680467-561B9AFA-A0CA-4E69-8EFB-100ECB132054Q34871636-99388E9C-7DEA-409D-A317-7C2B5F899E58Q35183649-2B58D2E9-778D-45C8-8460-B8C892F39EC5Q35300044-BDD70267-B54C-4BF4-84A8-AA9BC309A865Q35603055-8EA72171-2A10-4329-AD7A-29B2DCC7AB93Q35915932-767CB3A5-BA9E-41C2-B0AE-583CF20E3812Q36620076-513E97E5-2041-4864-86FF-CEC19AD23310Q36853578-1CCCB223-AD1B-4B9C-B5D0-08C0C14F9DB8Q36951933-6C564BB0-7E38-4B42-9DEA-798227942248Q36958324-2F37E156-A668-4AFA-8D69-1A05C579FBEAQ37627544-6F95D33D-AD73-4E97-9C10-3B873FE1BA95Q37793056-BFE8ADEC-DA6D-4C21-8578-767B0DBE321AQ37810986-D49F3F9F-F919-466F-A2D7-C66A3836ADFBQ37855801-0D0BD37B-E784-42C6-96F8-1C20A01A2B42Q37875115-0A28287A-CBAE-4838-8569-B4AFFCDDD5E8Q37986145-90B8B6A0-8395-4FB8-B2C0-BC296EA4F8CBQ38003174-C9FF31A8-1B3B-461F-8584-6466157BFC51Q38049379-B41521FC-E5C0-4720-A873-2D9DB316C7ADQ38050686-F8761C14-6866-4866-B575-7D2EA016A6DFQ38071700-95D9F964-64E8-443E-96ED-A37C9DAE2729Q38109095-5B791C45-01D1-4E69-A2EC-DB0C98120A6FQ38112823-704393E3-0A80-4F5C-B357-D6596D1184E4Q38129422-6E9BF149-7E12-4687-8790-FEC55A15EDD0Q38155218-03A7DFD2-A60E-46C4-9919-EDFCDEFBEEF7Q38243832-1453E4B1-95B8-4267-99B6-FFE2240E4CC7Q38379295-C68BC8AE-D973-4CCF-B6F7-1EA088D24FD8Q38663481-46523169-6A8B-47AE-A41A-45F10A9A4EB3Q38874222-5F5FE321-5200-44C6-BC4C-1C265B1597F4Q38888365-AEDB9685-CA43-4D73-8918-C51AF736232DQ38888369-8CD4FCD9-7A1F-4D53-97A2-C8A4D89F394CQ39140289-C2DF184E-4D23-4CCD-A2DE-6AA6E7F5E752Q40359311-55A1B77E-6A16-4097-9BC3-9F36589471A7Q42836431-25A24137-3272-4DFF-A19D-26AAA4F90B46
P2860
Different effects of the ABCG2 c.421C>A SNP on the pharmacokinetics of fluvastatin, pravastatin and simvastatin.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh-hant
name
Different effects of the ABCG2 ...... , pravastatin and simvastatin.
@en
Different effects of the ABCG2 ...... , pravastatin and simvastatin.
@nl
type
label
Different effects of the ABCG2 ...... , pravastatin and simvastatin.
@en
Different effects of the ABCG2 ...... , pravastatin and simvastatin.
@nl
prefLabel
Different effects of the ABCG2 ...... , pravastatin and simvastatin.
@en
Different effects of the ABCG2 ...... , pravastatin and simvastatin.
@nl
P2860
P356
P1433
P1476
Different effects of the ABCG2 ...... , pravastatin and simvastatin.
@en
P2093
Marja K Pasanen
Pertti J Neuvonen
P2860
P304
P356
10.2217/PGS.09.85
P577
2009-10-01T00:00:00Z